Cost effectiveness of a protocol using palivizumab in preterm infants
Fuente:
Redalyc
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Sociedad Española de Farmacia Hospitalaria
2017
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1876480986541195264 |
|---|---|
| author | Yolanda Hernández-Gago |
| author_facet | Yolanda Hernández-Gago |
| contents | Cost effectiveness of a protocol using palivizumab in preterm infants Yolanda Hernández-Gago Marina Lombardero-Pin Casilda Ortega de la Cruz Pablo A Maciuniak Alicia Díez del Pino Medicina Cost Neonate Premature Palivizumab effectiveness Objective: The main objective was to evaluate the cost-effectiveness of protocol use of palivizumab in premature established by consensus in our Hospital comparing it based on the recommendations of various Scientific Societies. As a secondary objective risk factors and severity of hospitalized patients attending the established protocol in our Hospital were analyzed.Methods: The study period was 4 seasons with the expanded protocol (retrospective data) versus 2 with restricted or agreed protocol (prospective data). The perspective of the study was the Health System, including the costs of hospitalization and palivizumab our center. The calculation of the effectiveness was determined with the admission rate of premature patients stratified by weeks of gestational age <29, <32; and <35.For the analysis of risk factors and severity in patients admitted seasons with the new protocol are collected prospectively clinical data and environmental and social factors.Results: In the range of gestational age <29 years old and <32 greater effectiveness of the extended protocol was not demonstrated against the consensus. Only more effective for EG <35 in the accumulated data and comparing seasons 12/13 and 08/09 to 13/14 for individual data was observed. This range has an associated incremental cost effectiveness ratio of € 53 250,07 (range: € 14 793,39 to € 90 446,47 for singles data and € 50 525,53 (€ 28 688.22 to € 211 575,65) for accumulated. The establishment of this protocol in our center meant an average saving per season € 169 911,51.A cost-effectiveness of the extended protocol appropriate relationship is found if the cost of palivizumab per patient was less than € 1 206,67 (calculated for maximum use of the vial) and a higher rate of hospitalization of 9.21%.Children entering the season with the new protocol (season 12/13 and 13/14) are 63.4% in children under 3 months and 90% are term infants who do not belong to any population at risk, while many of them have associated risk factors you vary as have school-age siblings, rural residence, parental smoking, poor educational background of parents, lack of artificial feeding and family history of allergy.Conclusions: The consensus protocol has not been a significant increase in hospitalization rates in preterm infants <32 weeks gestational age patients. In those <35 has been observed a higher rate of hospitalization, with a very unfavorable cost-effectiveness for all clinical scenarios valued relationship. 2017 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365962268003 https://www.redalyc.org/journal/3659/365962268003/ https://www.redalyc.org/journal/3659/365962268003/html/ https://www.redalyc.org/journal/3659/365962268003/365962268003.epub https://www.redalyc.org/journal/3659/365962268003/movil 10.7399/fh.2017.41.2.10565 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.2 Vol.41 |
| format | Artículo científico |
| id | redalyc_365962268003 |
| institution | Redalyc |
| language | en |
| publishDate | 2017 |
| publisher | Sociedad Española de Farmacia Hospitalaria |
| spellingShingle | Cost effectiveness of a protocol using palivizumab in preterm infants Yolanda Hernández-Gago Medicina Cost Neonate Premature Palivizumab effectiveness Cost effectiveness of a protocol using palivizumab in preterm infants Yolanda Hernández-Gago Marina Lombardero-Pin Casilda Ortega de la Cruz Pablo A Maciuniak Alicia Díez del Pino Medicina Cost Neonate Premature Palivizumab effectiveness Objective: The main objective was to evaluate the cost-effectiveness of protocol use of palivizumab in premature established by consensus in our Hospital comparing it based on the recommendations of various Scientific Societies. As a secondary objective risk factors and severity of hospitalized patients attending the established protocol in our Hospital were analyzed.Methods: The study period was 4 seasons with the expanded protocol (retrospective data) versus 2 with restricted or agreed protocol (prospective data). The perspective of the study was the Health System, including the costs of hospitalization and palivizumab our center. The calculation of the effectiveness was determined with the admission rate of premature patients stratified by weeks of gestational age <29, <32; and <35.For the analysis of risk factors and severity in patients admitted seasons with the new protocol are collected prospectively clinical data and environmental and social factors.Results: In the range of gestational age <29 years old and <32 greater effectiveness of the extended protocol was not demonstrated against the consensus. Only more effective for EG <35 in the accumulated data and comparing seasons 12/13 and 08/09 to 13/14 for individual data was observed. This range has an associated incremental cost effectiveness ratio of € 53 250,07 (range: € 14 793,39 to € 90 446,47 for singles data and € 50 525,53 (€ 28 688.22 to € 211 575,65) for accumulated. The establishment of this protocol in our center meant an average saving per season € 169 911,51.A cost-effectiveness of the extended protocol appropriate relationship is found if the cost of palivizumab per patient was less than € 1 206,67 (calculated for maximum use of the vial) and a higher rate of hospitalization of 9.21%.Children entering the season with the new protocol (season 12/13 and 13/14) are 63.4% in children under 3 months and 90% are term infants who do not belong to any population at risk, while many of them have associated risk factors you vary as have school-age siblings, rural residence, parental smoking, poor educational background of parents, lack of artificial feeding and family history of allergy.Conclusions: The consensus protocol has not been a significant increase in hospitalization rates in preterm infants <32 weeks gestational age patients. In those <35 has been observed a higher rate of hospitalization, with a very unfavorable cost-effectiveness for all clinical scenarios valued relationship. 2017 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365962268003 https://www.redalyc.org/journal/3659/365962268003/ https://www.redalyc.org/journal/3659/365962268003/html/ https://www.redalyc.org/journal/3659/365962268003/365962268003.epub https://www.redalyc.org/journal/3659/365962268003/movil 10.7399/fh.2017.41.2.10565 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.2 Vol.41 |
| title | Cost effectiveness of a protocol using palivizumab in preterm infants |
| topic | Medicina Cost Neonate Premature Palivizumab effectiveness |
| url | https://www.redalyc.org/articulo.oa?id=365962268003 https://www.redalyc.org/journal/3659/365962268003/ https://www.redalyc.org/journal/3659/365962268003/html/ https://www.redalyc.org/journal/3659/365962268003/365962268003.epub https://www.redalyc.org/journal/3659/365962268003/movil |